Business Insights: OTC Opportunities in Europe, the US and Japan

The developed OTC markets such as the US and UK are heavily reliant on Rx-to-OTC switching of "new generation" products as a means of generating growth.

Switching also plays an important role for less-developed markets (e.g. France, Spain, Italy, Japan), though in this case they are playing “catch-up” with the more developed markets. The “Power of Switch” was brought into sharp focus in 2009 with the first ever use of the Centralized Procedure for switching products throughout the European Union.

This comprehensive report provides background on market dynamics (including overall market size and therapeutic category size) for each of the core countries under analysis.

This report also examines products and categories that are likely to be switched in the future, regulatory changes that are likely to impact the OTC market, and provides growth forecasts to 2013. Included in the report are case studies for two of the most significant switches of recent years – i.e. Alli (orlistat) and Zocor (simvastatin).

Click here to view a sample of this report.

Key features of this report

• Comprehensive examination of recent trends and developments in the featured countries.
• Market sizes and category sizes in 7 core markets.
• Case studies of the switches of orlistat and statins.
• Examination of regulatory changes that are likely to impact upon OTC markets in the future

This report

• Provides a clear and concise understanding of the dynamics of the global OTC market.
• Demonstrates how the dynamics of the OTC markets in the various countries differ widely, but also how they relate to each other.
• Identifies and examines examples of successful switches, which can be used as a model for future switches.
• Highlights switches that failed and examines possible causes for failure.
• Allows marketers to plan ahead: Anticipating what switches are likely to take place in future; and take into account other regulatory changes that are likely to take place.

Key questions answered by this report

• What opinion do various stakeholders (i.e. consumers, regulators, manufacturers, healthcare professionals) have on Rx-to-OTC switches?
• What does the future hold for the global OTC market?
• What Rx-to-OTC switches might there be in the future?

Click here to view a sample of this report.